Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. [electronic resource]
Producer: 20081030Description: 171-83 p. digitalISSN:- 1618-7598
- Anastrozole
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Hormonal -- administration & dosage
- Breast Neoplasms -- drug therapy
- Cost-Benefit Analysis
- Female
- Humans
- Letrozole
- Markov Chains
- Neoplasm Recurrence, Local
- Neoplasms, Hormone-Dependent -- drug therapy
- Nitriles -- administration & dosage
- Postmenopause
- Quality of Life
- Randomized Controlled Trials as Topic
- Tamoxifen -- administration & dosage
- Triazoles -- administration & dosage
- United Kingdom -- epidemiology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.